| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Articles |
Endocrine-Genetics Unit/LIM 25, Department of Medicine, University of Sao Paulo School of Medicine (R.G.G., C.Y.H., N.A., S.P.A.T.), 01246903 Sao Paulo, Brazil; Division of Endocrinology, Federal University of Sergipe (M.H.A.-O., A.H.O.S., R.M.C.P., N.L.S.), 49060-100 Aracajo Sergipe, Brazil; Division of Endocrinology, Departments of Medicine (M.A.L., R.S.) and Pediatrics (M.A.L.), and the Ilyssa Center for Molecular Endocrinology (M.A.L., R.S.), The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287; and Department of Medicine, Division of Endocrinology, Tulane University, School of Medicine, Endocrine Section (C.Y.B.), New Orleans, Louisiana 70112
Address all correspondence and requests for reprints to: Dr. Rogério G. Gondo, Endocrine-Genetics Unit/LIM 25, Sao Paulo University School of Medicine, Avenue Dr. Arnaldo, 455/5th Floor, 01246903 Sao Paulo, Brazil. E-mail: gondo_rog{at}hotmail.com
Abstract
GH-releasing peptides (GHRPs) are synthetic peptides that bind to specific receptors and thereby stimulate the secretion of pituitary GH. In vivo it is uncertain whether these peptides act directly on somatotroph cells or indirectly via release of GHRH from the hypothalamus. In this study we compared the pituitary hormone response to GHRP-2 in 11 individuals with isolated GH deficiency (GHD) due to a homozygous mutation of the GHRH receptor (GHRH-R) gene and in 8 normal unrelated controls.
Basal serum GH levels were lower in the GHD group compared with controls [0.11 ± 0.11 (range, <0.04 to 0.38) vs. 0.59 ± 0.76 µg/L (range, 0.042.12 µg/L); P = 0.052]. After GHRP-2 administration there was a 4.5-fold increase in serum GH relative to baseline values in the GHD group (0.49 ± 0.41 vs. 0.11 ± 0.11 µg/L; P = 0.002), which was significantly less than the 79-fold increase in the control group (46.8 ± 17.6 vs. 0.59 ± 0.76 µg/L; P = 0.008). Basal and post-GHRP-2 serum levels of ACTH, cortisol, and PRL were similar in both groups. Basal levels of serum TSH were significantly higher in the GHD group than in the control group (3.23 ± 2.21 vs. 1.37 ± 0.34 µIU/mL; P = 0.003). TSH levels in both groups did not change after GHRP-2 administration.
These results suggest that an intact GHRH signaling system is not an absolute requirement for GHRP-2 action on GH secretion and that GHRP-2 has a GHRH-independent effect on pituitary somatotroph cells.
This article has been cited by other articles:
![]() |
R. D. Kineman and R. M. Luque Evidence that Ghrelin Is as Potent as Growth Hormone (GH)-Releasing Hormone (GHRH) in Releasing GH from Primary Pituitary Cell Cultures of a Nonhuman Primate (Papio anubis), Acting through Intracellular Signaling Pathways Distinct from GHRH Endocrinology, September 1, 2007; 148(9): 4440 - 4449. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Brabant GH releasing peptide 2 test: the holy grail of testing GH deficiency? Eur. J. Endocrinol., July 1, 2007; 157(1): 29 - 30. [Full Text] [PDF] |
||||
![]() |
L. S. Farhy, C. Y. Bowers, and J. D. Veldhuis Model-projected mechanistic bases for sex differences in growth hormone regulation in humans Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1577 - R1593. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Menezes Oliveira, C. Marques-Santos, J. A. Barreto-Filho, R. Ximenes Filho, A. V. de Oliveira Britto, A. H. Oliveira Souza, C. M. Prado, C. R. Pereira Oliveira, R. M. C. Pereira, T. de Almeida Ribeiro Vicente, et al. Lack of Evidence of Premature Atherosclerosis in Untreated Severe Isolated Growth Hormone (GH) Deficiency due to a GH-Releasing Hormone Receptor Mutation J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2093 - 2099. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. S. Alcantara, R. Salvatori, P. R. S. Alcantara, L. M. A. Nobrega, V. S. Campos, E. C. O. Oliveira, M. H. S. Oliveira, A. H. O. Souza, and M. H. Aguiar-Oliveira Thyroid Morphology and Function in Adults with Untreated Isolated Growth Hormone Deficiency J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 860 - 864. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Alba, D. Fintini, C. Y. Bowers, A. F. Parlow, and R. Salvatori Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse Am J Physiol Endocrinol Metab, November 1, 2005; 289(5): E762 - E767. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Misra, K. K. Miller, K. Kuo, K. Griffin, V. Stewart, E. Hunter, D. B. Herzog, and A. Klibanski Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E347 - E356. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Le Tissier, D. F. Carmignac, S. Lilley, A. K. Sesay, C. J. Phelps, P. Houston, K. Mathers, C. Magoulas, D. Ogden, and I. C. A. F. Robinson Hypothalamic Growth Hormone-Releasing Hormone (GHRH) Deficiency: Targeted Ablation of GHRH Neurons in Mice Using a Viral Ion Channel Transgene Mol. Endocrinol., May 1, 2005; 19(5): 1251 - 1262. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin Endocr. Rev., June 1, 2004; 25(3): 426 - 457. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. V. Dimaraki, C. A. Jaffe, C. Y. Bowers, P. Marbach, and A. L. Barkan Pulsatile and nocturnal growth hormone secretions in men do not require periodic declines of somatostatin Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E163 - E170. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Horvath, S. Diano, P. Sotonyi, M. Heiman, and M. Tschop Minireview: Ghrelin and the Regulation of Energy Balance--A Hypothalamic Perspective Endocrinology, October 1, 2001; 142(10): 4163 - 4169. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. G. Maheshwari, S. S. Pezzoli, A. Rahim, S. M. Shalet, M. O. Thorner, and G. Baumann Pulsatile growth hormone secretion persists in genetic growth hormone-releasing hormone resistance Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E943 - E951. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |